Taken together, tasquinimod affects AML cell survival and proliferation similar to gene silencing, by targeting mTOR-ER stress signaling, indicating the therapeutic potential of S100A9 as a novel target for the treatment of AML patients. Here, MTOR is linked to acute myeloid leukemia.